Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action (Review)

Oncology Letters

Volumn 5, Issue 1, 2012, Pages 19-24

  Xu, Yaping ^a   Sheng, Liming ^a   Mao, Weimin ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Epidermal growth factor receptor; Erlotinib; Esophageal carcinoma; Gefitinib; Tyrosine kinase inhibitor

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; OXALIPLATIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BARRETT ESOPHAGUS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG WITHDRAWAL; ESOPHAGITIS; ESOPHAGUS CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; GENETIC POLYMORPHISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; NEUTROPENIA; PANCREAS CANCER; RASH; RECEPTOR BINDING; REVIEW; SIDE EFFECT; THROMBOCYTE COUNT; VOMITING;

EID: 84869012799     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.994     Document Type: Review

References (52)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. McKenzie S, Mailey B, Artinyan A, Metchikian M, Shibata S, Kernstine K and Kim J: Improved outcomes in the management of esophageal cancer with the addition of surgical resection to chemoradiation therapy. Ann Surg Oncol 18: 551-558, 2011.
3. Mariette C, Taillier G, Van Seuningen I and Triboulet JP: Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg 78: 1177-1183, 2004.
4. Ruol A, Rizzetto C, Castoro C, et al: Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome? Ann Surg 252: 788-796, 2010.
5. Hironaka S, Ohtsu A, Boku N, et al: Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T (2-3) N (any) M (0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 57: 425-433, 2003.
6. Park BB, Im YH, Hwang IG, et al: Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. Invest New Drugs 26: 387-392, 2008.
7. Jin J, Xu X, Wang F, et al: Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. JThorac Oncol 4: 1017-1021, 2009.
8. Li Y, Wo JM, Ray MB, Jones W, Su RR, Ellis S and Martin RC: Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma. World J Gastroenterol 12: 928-934, 2006.
9. Gibault L, Metges JP, Conan-Charlet V, et al: Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 93: 107-115, 2005.
10. Hoshino M, Fukui H, Ono Y, et al: Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma. Pathobiology 74: 15-21, 2007.
11. Shaheen NJ, Crosby MA, Bozymski EM and Sandler RS: Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 119: 333-338, 2000.
12. Goldman A, Chen HD, Roesly HB, et al: Characterization of squamous esophageal cells resistant to bile acids at acidic pH: implication for Barrett's esophagus pathogenesis. Am J Physiol Gastrointest Liver Physiol 300: G292-G302, 2011.
13. Wang QS, Sabourin CL, Bijur GN, Robertson FM and Stoner GD: Alterations in transforming growth factor-alpha and epidermal growth factor receptor expression during rat esophageal tumorigenesis. Mol Carcinog 15: 144-153, 1996.
14. Gong L, Debruyne PR, Witek M, et al: Bile acids initiate lineage-addicted gastroesophageal tumorigenesis by suppressing the EGF receptor-AKT axis. Clin Transl Sci 2: 286-293, 2009.
15. Marx AH, Zielinski M, Kowitz CM, et al: Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. Histopathology 57: 418-426, 2010.
16. Yacoub L, Goldman H and Odze RD: Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. Mod Pathol 10: 105-112, 1997.
17. Andl CD, Mizushima T, Nakagawa H, et al: Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. JBiol Chem 278: 1824-1830, 2003.
18. Miller CT, Moy JR, Lin L, et al: Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res 9: 4819-4825, 2003.
19. Rygiel AM, Milano F, Ten Kate FJ, et al: Gains and amplifications of c-myc, EGFR, and 20. q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 17: 1380-1385, 2008.
20. Owonikoko T, Rees M, Gabbert HE and Sarbia M: Intratumoral genetic heterogeneity in Barrett adenocarcinoma. Am J Clin Pathol 117: 558-566, 2002.
21. Gebhardt F, Zänker KS and Brandt B: Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 274: 13176-13180, 1999.
22. Buerger H, Gebhardt F, Schmidt H, et al: Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 60: 854-857, 2000.
23. Tiseo M, Capelletti M, De Palma G, et al: Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. J Thorac Oncol3: 1104-1111, 2008.
24. Tzeng CW, Frolov A, Frolova N, et al: Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Ann Surg Oncol 14: 2150-2158, 2007.
25. Etienne-Grimaldi MC, Pereira S, Magné N, et al: Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. Ann Oncol 16: 934-941, 2005.
26. Brandt B, Meyer-Staeckling S, Schmidt H, Agelopoulos K and Buerger H: Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. Clin Cancer Res12: 7252-7260, 2006.
27. Gebhardt F, Bürger H and Brandt B: Modulation of EGFR gene transcription by a polymorphic repetitive sequence-a link between genetics and epigenetics. Int J Biol Markers 15: 105-110, 2000.
28. Amador ML, Oppenheimer D, Perea S, et al: An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 64: 9139-9143, 2004.
29. Lee JM, Yang SY, Yang PW, et al: Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery. Ann Surg Oncol 18: 2066-2073, 2011.
30. Upadhyay R, Jain M, Kumar S, Ghoshal UC and Mittal B: Interaction of EGFR 497Arg>Lys with EGF +61A>G polymorphism: modulation of risk in esophageal cancer. Oncol Res17: 167-174, 2008.
31. Jain M, Kumar S, Upadhyay R, Lal P, Tiwari A, Ghoshal UC and Mittal B: Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer. Cancer Biol Ther 6: 1553-1558, 2007.
32. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol22: 1103-1109, 2004.
33. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304: 1497-1500, 2004.
34. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
35. Kwak EL, Jankowski J, Thayer SP, et al: Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12: 4283-4287, 2006.
36. Pühringer-Oppermann FA, Stein HJ and Sarbia M: Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. Dis Esophagus 20: 9-11, 2007.
37. Sudo T, Mimori K, Nagahara H, et al: Identification of EGFR mutations in esophageal cancer. Eur J Surg Oncol 33: 44-48, 2007.
38. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al: Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol24: 1612-1619, 2006.
39. Kaneko K, Kumekawa Y, Makino R, et al: EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Front Biosci 15: 65-72, 2010.
40. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537, 2005.
41. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 25: 1960-1966, 2007.
42. Hara F, Aoe M, Doihara H, et al: Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines invitro and in vivo. Cancer Lett 226: 37-47, 2005.
43. Teraishi F, Kagawa S, Watanabe T, et al: ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett 579: 4069-4075, 2005.
44. Taira N, Doihara H, Oota T, et al: Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro. Acta Med Okayama 60: 25-34, 2006.
45. Ferry DR, Anderson M, Beddard K, et al: A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 13: 5869-5875, 2007.
46. Javle M, Pande A, Iyer R, et al: Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am J Clin Oncol 31: 329-334, 2008.
47. Rodriguez CP, Adelstein DJ, Rice TW, et al: A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol 5: 229-235, 2010.
48. Sunpaweravong P, Sunpaweravong S, Sangthawan D, Puttawibul P and Mitarnun W: Combination of gefitinib, cisplatin and 5-FU chemotherapy, and radiation therapy (RT) in newly-diagnosed patients with esophageal carcinoma. J Clin Oncol 25: 4605, 2007.
49. Dobelbower MC, Russo SM, Raisch KP, et al: Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anticancer Drugs 17: 95-102, 2006.
50. Ilson DH, Kelsen D, Shah M, et al: A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 117: 1409-1414, 2011.
51. Li G, Hu W, Wang J, et al: Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma. Int J Radiat Oncol Biol Phys 78: 1407-1412, 2010.
52. Ku GY and Ilson DH: Esophagogastric cancer: targeted agents. Cancer Treat Rev 36: 235-248, 2010.